Net Clinical Benefit as Measure of Treatment Benefit Among Older Adults With Advanced Incurable Non–Small Cell Lung Cancer

Net Clinical Benefit as Measure of Treatment Benefit Among Older Adults With Advanced Incurable Non–Small Cell Lung Cancer—Reply

Published:2023-08-01 Issue:8 Volume:9 Page:1154
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Voruganti Teja¹,Presley Carolyn J.²,Gross Cary P.³

Affiliation:

1. Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia

2. Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus

3. Section of General Internal Medicine, Department of Medicine, Yale School of Medicine, New Haven, Connecticut

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2806578/jamaoncology_voruganti_2023_lr_230017_1691789057.45746.pdf

Reference5 articles.

1. Association between age and survival trends in advanced non-small cell lung cancer after adoption of immunotherapy.;Voruganti;JAMA Oncol,2023

2. Speed of adoption of immune checkpoint inhibitors of programmed cell death 1 protein and comparison of patient ages in clinical practice vs pivotal clinical trials.;O’Connor;JAMA Oncol,2018

3. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes.;Ellis;J Clin Oncol,2014

4. ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers.;Cherny;ESMO Open,2016

5. Testing the effects of MK-3475 (pembrolizumab) with or without the usual chemotherapy treatment for patients 70 years of age and older with advanced non-small cell lung cancer. ClinicalTrials.gov identifier: NCT04533451. Updated April 18, 2023. Accessed May 16, 2023. https://clinicaltrials.gov/ct2/show/NCT04533451